Abstract
Cancer originating from germ cells is a special disease, characterized by increased incidence in young men (18–40 years) and extremely good prognosis, even if it is diagnosed in advanced stages. The vast majority of these cancers are originated in the gonads (testicles), while a small percentage of germ cell tumors may appear in midline extragonadal locations that are embryologically developed from the central crest (epiphysis, mediastinum, retro peritoneum).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Einhorn LH (2002) Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 99:4592–4595
Bosl GJ, Motzer RJ (1997) Testicular germ-cell cancer. N Engl J Med 337:242–253
Thomas GM, Rider WD, Dembo AJ et al (1982) Seminoma of the testis: results of treatment and patterns of failure after radiation therapy. Int J Radiat Oncol Biol Phys 8:165
Willan B, McGowan D (1985) Seminoma of the testis: a 22-year experience with radiation therapy. Int J Radiat Oncol Biol Phys 11:1769
Classen J, Schmidberger H, Meisner C et al (2003) Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21:1101
Chung PW, Warde PR, Panzarella T et al (2003) Appropriate radiation volume for stage IIA/B testicular seminoma. Int J Radiat Oncol Biol Phys 56:746
Warde P, Gospodarowicz M, Panzarella T et al (1998) Management of stage II seminoma. J Clin Oncol 16:290
Loehrer PJ, Birch R, Williams SD et al (1987) Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 5:1212
Rabbani F, Sheinfeld J, Farivar-Mohseni H et al (2001) Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 19:2020
Kondagunta GV, Motzer RJ (2002) Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors. Semin Urol Oncol 20:239
Williams SD, Stablein DM, Einhorn LH et al (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317:1433
Behnia M, Foster R, Einhorn LH (2000) Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. The Indiana University experience. Eur J Cancer 36:472
Kondagunta G, Sheinfeld J, Mazumdar M et al (2004) Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 22:464
Einhorn LH, Williams SD, Loehrer PJ et al (1989) Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 7:387, PubMed
Bosl GJ, Geller NL, Bajorin D et al (1988) A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6:1231, PubMed
de Wit R, Stoter G, Kaye SB et al (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cooperative Group. J Clin Oncol 15:1837
Loehrer PJ, Johnson DH, Elson P et al (1995) Importance of bleomycin in favorable prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 13:470
Bajorin DF, Sarosdy MF, Pfister DG et al (1993) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multi-institutional study. J Clin Oncol 11:598
Horwich A, Sleijfer D, Fossa S et al (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 15:1844
Toner GC, Stockler MR, Boyer MJ et al (2001) Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 357
de Wit R, Stoter G, Sleijfer DT et al (1995) Four cycles of BEP versus an alternating regimen of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma: a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71:1311
Nichols CR, Williams SD, Loehrer PJ et al (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163
Kaye S, Mead G, Fossa S et al (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16:692
Nichols CR, Catalano P, Crawford ED et al (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors; an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 16:1287
Motzer RJ, Mazumdar M, Gulati SC et al (1993) Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828
Motzer RJ, Mazumdar M, Bajorin DF et al (1997) High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15:2546
Schmoll H-J, Kollmannsberger C, Metzner JT et al (2003) Long-term results of first-line sequential high-dose VIP chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21:4083
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Mountzios, G. (2015). Germ-Cell Tumors. In: de Mello, R., Tavares, Á., Mountzios, G. (eds) International Manual of Oncology Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-21683-6_25
Download citation
DOI: https://doi.org/10.1007/978-3-319-21683-6_25
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-21682-9
Online ISBN: 978-3-319-21683-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)